MedDataX Logo

NIS for Patients Using Symbicort Turbuhaler for Maintenance and Reliever Therapy in a Single Inhaler

NCT ID: NCT00557297

Last Updated: 2008-09-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-10-31

Study Completion Date

2008-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this non-interventional study is to ensure that patients in routine clinical practice follow given treatment instructions and to evaluate the number of reliever inhalations as well as the number of patient/days with more than 8/12 total inhalations at any day. If the number of reliever inhalations and thus the received inhaled glucocorticosteroid dose is not excessive, the safety conclusions from the clinical studies can be extrapolated to real life for better acceptance of SMART (Symbicort Maintenance and Reliever Therapy).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

NIS-observe Treatment Efficacy in Maintaining Symptoms Control in Moderate/Severe Asthma With Symbicort SMART

NCT00785733

Moderate/Severe Asthma
COMPLETED

Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma

NCT00573222

Asthma
COMPLETED

Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia

NCT00576316

Asthma
COMPLETED PHASE4

Real Life Effectiveness in Asthma of Symbicort Single Inhaler Therapy

NCT00319306

Asthma
COMPLETED PHASE3

SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults

NCT00238784

Asthma
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Persistent asthma
* Prior Symbicort Turbuhaler maintenance and reliever therapy in a single inhaler
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Alūksne, , Latvia

Site Status

Research Site

Aozkraukle, , Latvia

Site Status

Research Site

Balvi, , Latvia

Site Status

Research Site

Cēsis, , Latvia

Site Status

Research Site

Gulbene, , Latvia

Site Status

Research Site

Jēkabpils, , Latvia

Site Status

Research Site

Jumprava, , Latvia

Site Status

Research Site

Krāslava, , Latvia

Site Status

Research Site

Kuldīga, , Latvia

Site Status

Research Site

Ķekava, , Latvia

Site Status

Research Site

Liepāja, , Latvia

Site Status

Research Site

Limbaži, , Latvia

Site Status

Research Site

Līvāni, , Latvia

Site Status

Research Site

Madona, , Latvia

Site Status

Research Site

Ogre, , Latvia

Site Status

Research Site

Preiļi, , Latvia

Site Status

Research Site

Rēzekne, , Latvia

Site Status

Research Site

Salacgrīva, , Latvia

Site Status

Research Site

Saldus, , Latvia

Site Status

Research Site

Talsi, , Latvia

Site Status

Research Site

Valniera, , Latvia

Site Status

Research Site

Ventspils, , Latvia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Latvia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

D5890L00031

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A 6 Months NIS to Evaluate the Use of Rescue Medication and Quality of Life in Adult Asthmatic Subjects Treated With Symbicort® SMART®
NCT00884689 COMPLETED
A Follow-up Survey to Compare Stable Dosing (SERETIDE) With SYMBICORT, SMART, Maintenance and Reliever Therapy in One Inhaler in Moderate and Severe Asthmatics.
NCT00858286 COMPLETED PHASE4
Evaluating the Symbicort Turbuhaler (Formoterol/Budesonide) Maintenance and Reliever Therapy for Asthma in Daily Practice
NCT00782314 COMPLETED
Symbicort SMART (Symbicort Maintenance And Reliever Therapy)
NCT00523679 COMPLETED
A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice
NCT00505388 COMPLETED
A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®
NCT00532922 COMPLETED
CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.
NCT00479739 COMPLETED PHASE4
Symbicort Usage in Asthma Treatment and Impact of a New Therapeutic Strategy on Compliance and Asthma Control in France
NCT00812357 COMPLETED
Relative Bronchodilating Effects of Formoterol When Administered Via Symbicort Pressurized Metered-dose Inhaler (pMDI) or Oxis Turbuhaler
NCT00658255 COMPLETED PHASE2
SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent Asthma
NCT00290264 COMPLETED PHASE3
Clinical Experience Investigation of Symbicort Turbuhaler as Maintenance Therapy and Reliever Therapy
NCT01711840 COMPLETED
A Pharmaceopidemiological Study in Patients Who Use Symbicort SMART
NCT00503061 COMPLETED
Asthma Control-A "Patient Follow up Programme" Maintenance and Reliever Therapy in a Single Inhaler
NCT00524641 COMPLETED
Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults
NCT00385593 TERMINATED PHASE3
Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma
NCT00255255 COMPLETED PHASE3
DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults
NCT00252863 COMPLETED PHASE3
New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day
NCT01360021 COMPLETED PHASE3
Study to Investigate the Efficacy of Symbicort® SMART.
NCT00839800 COMPLETED PHASE3
A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents
NCT01444430 COMPLETED PHASE3
Symbicort Rapihaler Therapeutic Equivalence Study
NCT00536731 COMPLETED PHASE3
Cost-effectiveness Study of Symbicort as Maintenance and Reliever Therapy (SMART)
NCT00937066 COMPLETED
Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Single & Repeat Doses of GSK2269557
NCT01462617 COMPLETED PHASE1
Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma
NCT00536913 COMPLETED PHASE3
Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids
NCT00353873 COMPLETED PHASE4
Real Life Effectiveness in Patients With Not Optimally Controlled Asthma
NCT00784953 COMPLETED